While Palantir's hare price has enjoyed a massive spike, one lingering concern is the company's ability to sustain this momentum.

CEO Dikla Czaczkes Akselbrad highlighted the recommendation by the independent Data Safety Monitoring Board (DSMB) to conclude the SHIELD II Phase 3 trial for D-PLEX100 upon the enrollment of 800 ...

Full-year sales reached $26.8 billion, driven by robust performance across HIV, oncology, and liver disease portfolios. HIV sales grew 8% year-over-year to $19.6 billion in 2024, exceeding ...

Management projected Q4 2025 revenue growth of 50%-53% year-over-year, supported by delayed Q3 shipments being accounted for in the current quarter. Revenue for Q1 2026 is expected to align with Q1 ...